@hubermanlab

“PEPTIDE SOURCES & SAFETY • - My guest on the Huberman Lab podcast out now is Dr Abud Bakri, MD @abud_bakri We discuss peptides: BPC, GLPs (incl Retatrutide), GHK-Cu, Pinealon, Epitalon, TB500 and Thymosin, and more. The topic of sourcing came up and broadly speaking there are four categories: 1) Pharma (brand name): highest stringency, with respect to purity. 2) Compounding Pharmacies: here, there’s a huge range of quality, purity, and cost. There are some excellent compounding pharmacies out there. We discussed the more reputable ones on the podcast. This source still requires a prescription. 3) Gray Market: compounds being sold without prescription labeled “for research purposes only, not for animal or human use”. The range of quality and purity is vast. 4) Black market: not *necessarily* “home grown” but zero validation about what you’re taking. In theory, this is also a problem with certain gray market sources, but even more extreme with black market sources. The episode gets into the fact that for some peptides— in particular the GLPs/Reta there are randomized controlled trials to support their specific uses, (also true for Melanotan and GH secretagouges) but many people are taking these compounds for things other than what they were studied and approved for. (Off label use of FDA compounds is not on unusual but typically it’s a doctor making those decisions not the patient). For anyone who is peptide curious, skeptical, or anti-peptides (that are not studied with randomized control trials) as well as people who are very pro peptides will benefit from listening to the episode. You can find it at hubermanlab.com & on all podcast platforms. Thank you for your interest in science! @stanford @stanford.med”

Claim 1 (GLP-1 RAs / Retinoids) is strongly supported by human RCT evidence, including active Phase 3 trials. Claim 2 (Melanotan and GH secretagogues with RCT support) finds no clinical trial evidence and should be rated no_evidence. Claim 3 (BPC-157 for post-exercise injury) is supported by consistent preclinical data (animal models) and aligns with documented healing mechanisms, though human trials are lacking. Overall, the peptide claims range from well-supported (GLP-1) to preclinically sound but clinically unvalidated (BPC-157) to unsupported by trial data (Melanotan/GH secretagogues).

“Comment HUNGER & I’ll DM you a link to the full episode. MILD SLEEP LOSS IMPACTS MEN’S VS WOMEN’S HORMONES & HUNGER DIFFERENTLY • - My guest on the Huberman Lab podcast out now is Dr. Marie-Pierre St-Onge, PhD⁠, professor of nutritional medicine at Columbia University School of Medicine @columbiamed and an expert on the bidirectional relationship between nutrition and sleep. We discuss how even moderate sleep loss increases appetite, changes hunger-related hormones, and causes weight gain, even when calories are not increased. We also explain how meal timing and specific foods, like fiber, ginger, saturated fat, and various oils, affect sleep onset, sleep quality, and metabolism. Throughout the conversation, we discuss specific foods and diets that directly support weight loss, better sleep, and long-term cardiometabolic health. Comment HUNGER & I’ll DM you a link to the full episode. You can also find the episode by going to Hubermanlab on any of the major podcast platforms: @spotifypodcasts @applepodcasts etc Please put any questions you might have in the comments section below this post and as always, thank you for your interest in science! @stanford @stanford.med #neuroscience #science #ciencia #neurociencia”

All six claims are scientifically supported by published human and preclinical evidence. The mechanistic chain—sleep restriction increases ghrelin and reduces GLP-1, leading to increased hunger and caloric intake in women—is grounded in peer-reviewed endocrinology, sleep medicine, and behavioral nutrition literature. The specific 300-calorie increase figure aligns with documented effect sizes from controlled human feeding studies. No contradictions or significant overstatements were identified.